Assignee
REGENXBIO INC
US·6 granted patents·69 pending applications·2 citations·filing 2017–2025
Top patents by PatentIndex Score
75 records- 0178US11986515B2Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS)REGENXBIO INC·Filed 2023·Granted May 21, 2024·1 cites·30 claims
- 0276US2025367326A1Microdystrophin nucleic acid gene therapy constructs and uses thereofREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0376US2025367328A1Methods of manufacturing microdystrophin gene therapy constructsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0476US2025367327A1Treatment of dystrophinopathies with microdystrophin gene therapy constructsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0572US2024254214A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2023·Application pending·0 cites
- 0671US11613739B2Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cellsREGENXBIO INC·Filed 2018·Granted Mar 28, 2023·1 cites·16 claims
- 0770US2025312492A1Microdystrophin gene therapy administration for treatment of dystrophinopathiesREGENXBIO INC·Filed 2025·Application pending·0 cites
- 0867US2025051740A1Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cellsREGENXBIO INC·Filed 2024·Application pending·0 cites
- 0966US2023057519A1Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1066US2025186904A1Anion exchange chromatography for recombinant aav productionREGENXBIO INC·Filed 2024·Application pending·0 cites
- 1165US2024216543A1Microdystrophin gene therapy administration for treatment of dystrophinopathiesREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1265US2025249127A1Gene therapy for treating an ocular diseaseREGENXBIO INC·Filed 2023·Application pending·0 cites
- 1365US2025215401A1Compositions and methods for recombinant aav productionREGENXBIO INC·Filed 2023·Application pending·0 cites
- 1464US2025320287A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2025·Application pending·0 cites
- 1563US2023270886A1Microdystrophin gene therapy constructs and uses thereofREGENXBIO INC·Filed 2020·Application pending·0 cites
- 1663US2024050537A1Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)REGENXBIO INC·Filed 2023·Application pending·0 cites
- 1763US2025230465A1Compositions and methods for recombinant aav productionREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1861US2025277004A1Hybrid aav capsidsREGENXBIO INC·Filed 2023·Application pending·0 cites
- 1961US2026055144A1Recombinant adeno-associated viruses and uses thereofREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2060US2025213727A1Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapyREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2160US2025288697A1Vectorized anti-tnf-alpha inhibitors for ocular indicationsREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2259US2026034246A1Vectorized anti-complement antibodies and complement agents and administration thereofREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2359US2025207126A1Modified muscle-specific promotersREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2458US2024167054A1Method of producing a recombinant virus particleREGENXBIO INC·Filed 2021·Application pending·0 cites
- 2558US2024358857A1Treatment of duchenne muscular dystrophy and combinations thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 2658US2026042993A1Scalable clarification process for recombinant aav productionREGENXBIO INC·Filed 2025·Application pending·0 cites
- 2757US2025276097A1Fully-human post-translationally modified antibody therapeuticsREGENXBIO INC·Filed 2025·Application pending·0 cites
- 2857US2026034243A1Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoroidal administrationREGENXBIO INC·Filed 2023·Application pending·0 cites
- 2957US2023390418A1Vectorized factor xii antibodies and administration thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 3056US2025001006A1Recombinant adeno-associated viruses for targeted deliveryREGENXBIO INC·Filed 2022·Application pending·0 cites
- 3156US2024384292A1Vectorized tnf-alpha antagonists for ocular indicationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 3256US2024309076A1Tau-specific antibody gene therapy compositions, methods and uses thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 3356US2019211091A1Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2019·Application pending·0 cites
- 3455US2025179518A1Recombinant adeno-associated viruses for cns tropic deliveryREGENXBIO INC·Filed 2022·Application pending·0 cites
- 3555US2020277364A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2018·Application pending·0 cites
- 3655US2024425572A1Antibodies and methods of using thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 3754US12070702B2Anion exchange chromatography for recombinant AAV productionREGENXBIO INC·Filed 2019·Granted Aug 27, 2024·0 cites·13 claims
- 3854US2024117328A1Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)REGENXBIO INC·Filed 2022·Application pending·0 cites
- 3954US2024218397A1Novel aav vectors and methods and uses thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 4053US2023381341A1Adeno-associated viruses for ocular delivery of gene therapyREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4152US2025339555A1Formulations for suprachoroidal administration such as formulations with aggregate formationREGENXBIO INC·Filed 2023·Application pending·0 cites
- 4252US2025326861A1Vectorized lanadelumab and administration thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4351US2023374541A1Recombinant adeno-associated viruses for cns or muscle deliveryREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4450US2025025574A1Engineered nucleic acid regulatory elements and methods and uses thereofREGENXBIO INC·Filed 2022·Application pending·0 cites
- 4550US2019127455A1Treatment of Ocular Diseases with Fully- Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2017·Application pending·0 cites
- 4650US2021324483A1Method for measuring the infectivity of replication defective viral vectors and virusesREGENXBIO INC·Filed 2019·Application pending·0 cites
- 4750US2024124890A1Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereofREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4850US2023391864A1Vectorized anti-tnf-alpha antibodies for ocular indicationsREGENXBIO INC·Filed 2021·Application pending·0 cites
- 4949US12365865B2Scalable clarification process for recombinant AAV productionREGENXBIO INC·Filed 2019·Granted Jul 22, 2025·0 cites·17 claims
- 5049US2026034250A1Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fabREGENXBIO INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 75 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when REGENXBIO INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →